Difference between revisions of "Radotinib (Supect)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Chronic myelogenous leukemia" to "Category:Chronic myeloid leukemia") |
||
(4 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
+ | '''Not currently approved in the United States.''' | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=723999 NCI Drug Dictionary]: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. | |
− | == | + | ==Diseases for which it is used== |
− | + | *[[Chronic myeloid leukemia]] | |
− | |||
− | + | ==Also known as== | |
− | [[Category: | + | *'''Code name:''' IY5511HCl |
+ | *'''Brand name:''' Supect | ||
+ | |||
+ | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | + | ||
[[Category:Bcr-Abl inhibitors]] | [[Category:Bcr-Abl inhibitors]] | ||
+ | [[Category:PDGFR inhibitors]] | ||
− | [[Category:Chronic | + | [[Category:Chronic myeloid leukemia medications]] |
− | [[Category: | + | [[Category:KFDA approved drugs]] |
Latest revision as of 23:44, 26 September 2022
Not currently approved in the United States.
Mechanism of action
From the NCI Drug Dictionary: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.
Diseases for which it is used
Also known as
- Code name: IY5511HCl
- Brand name: Supect